Abstract
Eicosanoids have been the major therapeutic targets in rheumatoid arthritis and other degenerative diseases where inflammation is involved. In the past decade, the biological significance of eicosanoids and their potential as therapeutic targets in cancer have also been recognized and is now a focal area of research in many laboratories. Recently, phospholipase A2 (PLA2), the enzyme responsible for arachidonic acid supply to eicosanoid-producing enzymes has attracted attention. It has been proposed that PLA2 inhibition can yield a better therapeutic outcome than inhibition of individual eicosanoid-producing enzymes. In this article, we focus on the rationale for targeting arachidonic acideicosanoid pathways as well as evaluate the recent patents that identify inhibitors of the PLA2 family of enzymes.
Keywords: Eicosanoids, cyclooxygenase, lipoxygenase, secreted phospholipase A2, cytosolic phospholipase A2, annexin A1, annexin A2
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title: Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Volume: 2 Issue: 1
Author(s): Qihan Dong, Marzieh Niknami, Manish Patel and Paul Witting
Affiliation:
Keywords: Eicosanoids, cyclooxygenase, lipoxygenase, secreted phospholipase A2, cytosolic phospholipase A2, annexin A1, annexin A2
Abstract: Eicosanoids have been the major therapeutic targets in rheumatoid arthritis and other degenerative diseases where inflammation is involved. In the past decade, the biological significance of eicosanoids and their potential as therapeutic targets in cancer have also been recognized and is now a focal area of research in many laboratories. Recently, phospholipase A2 (PLA2), the enzyme responsible for arachidonic acid supply to eicosanoid-producing enzymes has attracted attention. It has been proposed that PLA2 inhibition can yield a better therapeutic outcome than inhibition of individual eicosanoid-producing enzymes. In this article, we focus on the rationale for targeting arachidonic acideicosanoid pathways as well as evaluate the recent patents that identify inhibitors of the PLA2 family of enzymes.
Export Options
About this article
Cite this article as:
Dong Qihan, Niknami Marzieh, Patel Manish and Witting Paul, Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2008; 2 (1) . https://dx.doi.org/10.2174/187221408783421291
DOI https://dx.doi.org/10.2174/187221408783421291 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Synthesis, Antitumor Activity and Molecular Docking Studies on Seven Novel Thiazacridine Derivatives
Combinatorial Chemistry & High Throughput Screening Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Stereotactic Body Radiotherapy (SBRT) in the Management of Clinically Localized Prostate Cancer: Where are We Now?
Current Cancer Therapy Reviews Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening
Endocrine, Metabolic & Immune Disorders - Drug Targets Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Letters in Drug Design & Discovery PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry